[Serum protein binding and elimination half-lives of naproxen in patients with hepatocellular or obstructive icterus (author's transl)].
Serum protein binding of (+)-6-methoxy-alpha-methyl-2-naphthaline acetic acid (naproxen) is considerably reduced in patients with hepatocellular or obstructive icterus, respectively. There is a significant negative correlation between serum bilirubin concentration and serum protein binding of naproxen. However, bilirubin cannot be responsible exclusively for the reduced naproxen binding. This has been shown by studies with serum to which bilirubin was added in vitro. The hypothetical plasma concentration at the time zero and the half-lives of naproxen were not altered in patients with hepatocellular or obstructive icterus in comparison with healthy subjects. This may possibly cause an increased pharmacologic effect of naproxen in icteric patients when the drug is administered in usual doses. For in this case the pharmacologically active unbound part of the drug must be increased.
D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000378:metabolism*; D002779:Cholestasis / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007565:Jaundice / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000097:blood*; D011485:Protein Binding
D001798:Blood Proteins; D009288:Naproxen
Serumprotein bindung und Eliminationshalbwertszeiten von Naproxen bei Patienten mit hepatozellulärem bzw. obstruktivem Ikterus.